New insider activity at Rapport Therapeutics, Inc. ( (RAPP) ) has taken place on March 14, 2025.
In recent transactions involving Rapport Therapeutics, Inc. stock, Director Wendy B. Young acquired 6,000 shares valued at $61,200. Additionally, VP Troy Ignelzi purchased 10,000 shares, amounting to $100,988. These strategic investments by key executives highlight their confidence in the company’s future prospects.
Recent Updates on RAPP stock
Rapport Therapeutics, Inc. recently released its Q4 earnings report, showcasing significant progress in its lead program, RAP-219, which targets neurological and psychiatric disorders. The company reported a net loss of $20 million due to increased R&D and administrative expenses but maintains a strong cash position of $305.3 million, expected to fund operations through 2026. Key developments include promising trial results for RAP-219, the appointment of a new chief medical officer, and plans for further clinical trials in 2025. Trading of Rapport’s stock was temporarily halted due to volatility but has since resumed. These developments, particularly the promising trial results and leadership changes, have influenced market perceptions and price target considerations.
More about Rapport Therapeutics, Inc.
YTD Price Performance: -45.57%
Average Trading Volume: 172,942
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $327.7M